Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8520402 | 0.86 | ADAM17 (0.45) | POLBEPHX2ALDH1A1MEN1KMT2A | |
| SCHEMBL13014827 | 0.81 | EPHX2 (0.50) | POLBEPHX2HPGDMAPT | |
| SCHEMBL21514108 | 0.74 | EPHX2 (0.61) | POLBEPHX2ALDH1A1MEN1KMT2A | |
| SCHEMBL7674546 | 0.72 | POLB (0.67) | POLBALDH1A1HPGDCNR2MEN1 | |
| Hydrochloric Acid SCHEMBL27634849 | 0.70 | POLB (0.65) | POLBALDH1A1HPGDCNR2MEN1 | |
| SCHEMBL5993629 | 0.68 | EPHX2 (0.52) | EPHX2ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL10211615 | 0.68 | EPHX2 (0.64) | EPHX2ALDH1A1MEN1KMT2ASIGMAR1 | |
| SCHEMBL6385132 | 0.67 | EPHX2 (0.64) | EPHX2ALDH1A1MEN1KMT2ASIGMAR1 | |
| SCHEMBL16672173 | 0.67 | POLB (0.55) | POLBALDH1A1HPGDCNR2MEN1 | |
| SCHEMBL13105233 | 0.67 | GBA1 (0.51) | CYP3A4TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20100317568-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317568-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | POLB 138/4885EPHX2 3893/4885CYP3A4 1792/4885 |
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | POLB 138/4885EPHX2 3893/4885CYP3A4 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.